193 related articles for article (PubMed ID: 15802034)
1. Lymphocyte PC-1 activity in patients on maintenance haemodialysis treated with human erythropoietin and 1-alpha-D3.
Stefanovic V; Djordjevic V; Ivic M; Mitic-Zlatkovic M; Vlahovic P
Ann Clin Biochem; 2005 Jan; 42(Pt 1):55-60. PubMed ID: 15802034
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
3. Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus.
Stefanović V; Antić S
Clin Lab; 2004; 50(5-6):271-8. PubMed ID: 15209435
[TBL] [Abstract][Full Text] [Related]
4. Reversal of increased lymphocyte PC-1 activity in patients with type 2 diabetes treated with metformin.
Stefanović V; Antić S; Mitic-Zlatković M; Vlahović P
Diabetes Metab Res Rev; 1999; 15(6):400-4. PubMed ID: 10634965
[TBL] [Abstract][Full Text] [Related]
5. [Does long-term erythropoietin therapy influence the prevalence of serum markers of hepatitis B and C in haemodialysed uraemic patients?].
Mesjasz J; Wiecek A; Gonciarz Z; Mazur W; Kokot F
Pol Merkur Lekarski; 2004 Apr; 16(94):362-7. PubMed ID: 15517934
[TBL] [Abstract][Full Text] [Related]
6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
7. Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients.
Abe M; Okada K; Soma M; Matsumoto K
Clin Nephrol; 2011 Jan; 75(1):49-58. PubMed ID: 21176750
[TBL] [Abstract][Full Text] [Related]
8. [Influence of long-term human recombinant erythropoietin treatment on secretion of pancreatic polypeptide and gastrin in hemodialysed patients with chronic renal failure].
Nieszporek T; Kokot F; Wiecek A; Marcinkowski W; Rudka R; Trembecki J
Przegl Lek; 1995; 52(12):590-3. PubMed ID: 8834657
[TBL] [Abstract][Full Text] [Related]
9. [Influence of erythropoietin on immunological system of patients with chronic renal failure].
Debska-Slizień A; Rutkowski B; Manitius J; Zdrojewski Z; Szołkiewicz M; Bułło B; Lizakowski S; Myśliwska J; Myśliwski A; Bryl E; Trzonkowski P; Bakowska A; Rachoń D
Pol Merkur Lekarski; 2003 Oct; 15(88):326-7; discussion 327-9. PubMed ID: 14974359
[TBL] [Abstract][Full Text] [Related]
10. Influence of long-term erythropoietin treatment on insulin, glucagon, pancreatic polypeptide, and gastrin secretion in haemodialysed patients.
Kokot F; Nieszporek T; Wiecek A; Marcinkowski W; Rudka R; Trembecki J
Nephrol Dial Transplant; 1994; 9 Suppl 3():35-9. PubMed ID: 8072722
[TBL] [Abstract][Full Text] [Related]
11. Determinants of soluble CD23 antigen levels in hemodialysis patients: effect of 1.25 dihydroxyvitamin D3 and recombinant human erythropoietin treatment.
Altun B; Erdem Y; Usalan C; Arici M; Haznedaroglu IC; Yasavul U; Turgan C; Caglar S; Kirazli S
Clin Nephrol; 1999 Oct; 52(4):230-8. PubMed ID: 10543325
[TBL] [Abstract][Full Text] [Related]
12. Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients.
Messa P; Nicolini MA; Cesana B; Brezzi B; Zattera T; Magnasco A; Moroni G; Campise M
Nephrol Dial Transplant; 2006 Feb; 21(2):431-6. PubMed ID: 16249199
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience].
de Sousa FT; Prata MM; Barbas JV; dos Santos JP
Acta Med Port; 1990; 3(6):347-52. PubMed ID: 2089856
[TBL] [Abstract][Full Text] [Related]
14. Effects of erythropoietin on glucose tolerance in hemodialysis patients.
Chagnac A; Weinstein T; Zevin D; Korzets A; Hirsh J; Gafter U; Levi J
Clin Nephrol; 1994 Dec; 42(6):398-400. PubMed ID: 7882604
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
16. Effect of short-term rHuEPO treatment on insulin resistance in haemodialysis patients.
Spaia S; Pangalos M; Askepidis N; Pazarloglou M; Mavropoulou E; Theodoridis S; Dimitrakopoulos K; Milionis A; Vayonas G
Nephron; 2000 Apr; 84(4):320-5. PubMed ID: 10754408
[TBL] [Abstract][Full Text] [Related]
17. Effect of iron loading on peripheral blood lymphocyte subsets and on circulating cytokine levels in iron-depleted hemodialysis patients receiving erythropoietin.
Tsouchnikas I; Tsilipakou M; Daniilidis M; Kyriazis G; Pasadakis P; Parapanissiou E; Vargemezis V; Tsakiris D
Nephron Clin Pract; 2007; 107(3):c97-102. PubMed ID: 17890877
[TBL] [Abstract][Full Text] [Related]
18. [Effect of erythropoietin therapy on alpha receptor density in chronic dialysis patients].
Fritschka E; Neumayer HH; Seddighi S; Distler A; Philipp T
Med Klin (Munich); 1991 Jul; 86(7):353-9. PubMed ID: 1656181
[TBL] [Abstract][Full Text] [Related]
19. [The effect of hemodialysis on levels of beta-endorphin in serum of patients with chronic renal failure treated with erythropoietin].
Burak W; Grzeszczak W; Trelewicz P; Zukowska-Szczechowska E
Przegl Lek; 1996; 53(2):54-7. PubMed ID: 8754321
[TBL] [Abstract][Full Text] [Related]
20. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
